Innate Pharma strengthens leadership team
French immuno-oncology company Innate Pharma (Euronext: IPH) today announced that it has strengthened its leadership and corporate governance with the appointment of two new executive board members.
Arvind Sood, executive vice president (EVP), president of US Operations, Dr Sonia Quaratino, EVP, chief medical officer are thus joining Hervé Brailly, interim chief executive and Yannis Morel, EVP, chief operating officer.
Yannis Morel, current EVP, business development and product portfolio strategy and member of the executive board broadens his remit to become EVP, chief operating officer extending his operational responsibility to the management of research and early development, working with Innate Pharma chief scientific officer Prof Eric Vivier, and chief development officer, Nicola Beltraminelli.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze